Is HPV vaccination in pregnancy safe?

Bonde, Ulla; Joergensen, Jan Stener; Lamont, Ronald F.; Mogensen, Ole

doi:10.1080/21645515.2016.1160178

Cited by 26 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Safety of HPV vaccines in pregnancy or immediately pre-conceptually has been reviewed ( 230 ). The HPV vaccination concerns were not only the maternal safety, but also (and more) on the teratogenicity and other fetal adverse events (AEs) following HPV vaccination, including spontaneous miscarriage, preterm birth, congenital malformations, and fetal decease.…”

Section: Hpv Diseasementioning

confidence: 99%

“…For the fetal safety, none of the studies reported a significant increased rate of spontaneous abortion and other fetal outcomes in overall subgroup analyses (e.g., age, interval of time of conception and nearest vaccination, number of vaccinations) compared with controls. The conclusion was the risk of AEs during pregnancy is unrelated to HPV vaccination before or during pregnancy ( 230 ).…”

Section: Hpv Diseasementioning

confidence: 99%

See 1 more Smart Citation

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

Dadar

Chakraborty²,

Dhama

et al. 2018

Front. Immunol.

View full text Add to dashboard Cite

Human papillomavirus (HPV) is a viral infection with skin-to-skin based transmission mode. HPV annually caused over 500,000 cancer cases including cervical, anogenital and oropharyngeal cancer among others. HPV vaccination has become a public-health concern, worldwide, to prevent the cases of HPV infections including precancerous lesions, cervical cancers, and genital warts especially in adolescent female and male population by launching national programs with international alliances. Currently, available prophylactic and therapeutic vaccines are expensive to be used in developing countries for vaccination programs. The recent progress in immunotherapy, biotechnology, recombinant DNA technology and molecular biology along with alternative and complementary medicinal systems have paved novel ways and valuable opportunities to design and develop effective prophylactic and therapeutic vaccines, drugs and treatment approach to counter HPV effectively. Exploration and more researches on such advances could result in the gradual reduction in the incidences of HPV cases across the world. The present review presents a current global scenario and futuristic prospects of the advanced prophylactic and therapeutic approaches against HPV along with recent patents coverage of the progress and advances in drugs, vaccines and therapeutic regimens to effectively combat HPV infections and its cancerous conditions.

show abstract

Section: Hpv Diseasementioning

confidence: 99%

Section: Hpv Diseasementioning

confidence: 99%

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

Dadar

Chakraborty²,

Dhama

et al. 2018

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Comments Bearing in mind the paucity of research in his area, the authors should consider citing the review of adverse outcomes of pregnancy in association with HPV ( Bonde U, et al The potential role of HPV vaccination in the prevention of infectious complications of pregnancy 1 .The authors should consider alluding to the safety or otherwise of HPV vaccination in pregnancy ( Bonde U, et al Is HPV vaccination in pregnancy safe? 2 ). The study by Bruinsma (cited as Reference 14) had significant flaws and these were highlighted in the subsequent correspondence(Lamont RF, Sarhanis P. Precancerous changes in the cervix and risk of subsequent preterm birth 3 ).…”

mentioning

confidence: 99%

HPV infection and pre-term birth: a data-linkage study using Scottish Health Data

Aldhous¹,

Bhatia²,

Pollock³

et al. 2019

Wellcome Open Res

View full text Add to dashboard Cite

Background: We aimed to investigate whether infection with high-risk (HR) types of human papilloma virus (HPV) or HPV-associated cervical disease were associated with preterm birth (<37 weeks gestation). In a sub-group of younger women who were eligible for the HPV vaccine, we aimed to determine whether prior vaccination against the specific HPV-types, HPV-16 and -18 modified preterm birth risk. Methods: This was a data-linkage study, which linked HPV-associated viral and pathological information (from the Scottish HPV Archive) from women aged 16-45 years to routinely collected NHS maternity- and hospital-admission records from 1999–2015. Pregnancy outcomes from 5,598 women with term live birth (≥37 weeks gestation, n=4,942), preterm birth (<37 weeks gestation, n=386) or early miscarriage (<13 weeks gestation, n=270). Of these, data from HPV vaccine-eligible women (n=3,611, aged 16-25 years) were available, of whom 588 had been vaccinated. HPV-associated disease status was defined as: HR HPV-positive no disease, low-grade abnormalities or high-grade disease. Results: High-grade HPV-associated cervical disease was associated with preterm birth (odds ratio=1.843 [95% confidence interval 1.101–3.083], p=0.020) in adjusted binary logistic regression analysis, in all women, but there were no associations with HR HPV-infection alone or with low-grade abnormalities. No associations between any HPV parameter and preterm birth were seen in vaccine-eligible women, nor was there any effect of prior vaccination. Conclusions: HPV-associated high-grade cervical disease was associated with preterm birth, but there were no associations with HR HPV-infection or low-grade cervical disease. Thus HPV-infection alone (in the absence of cervical disease) does not appear to be an independent risk factor for preterm birth. For women who have undergone treatment for CIN and become pregnant, these results demonstrate the need to monitor for signs of preterm birth.

show abstract

“…In pregnancy, the true safety of the HPV vaccination has not yet been established through randomized controlled trial. Hence, the HPV vaccine administration to the pregnant women has not yet been approved [132].…”

Section: Hpv Vaccination During Pregnancymentioning

confidence: 99%

Human Papillomavirus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism of Self-Clearance

Pradhan¹,

Mahata²,

Ghosh³

et al. 2020

Human Papillomavirus

View full text Add to dashboard Cite

Young women are at the maximum risk of Human papillomavirus (HPV) infection which are asymptomatic in a majority of cases and spontaneously get cleared. Women in the age between 20 and 35 years are more active sexually and especially in the developing nations, this age group forms a major cohort among the population of pregnant women. The changed hormonal milieu and immune response during pregnancy might favor presence or persistence of HPV infection, while at the same time natural clearance also takes place during pregnancy with an unknown mechanism. Various HPVs have been reported to be associated with preterm rupture of membranes (PROM), fetal growth restriction (FGR), preeclampsia, placental abnormalities and preterm delivery in several populations. The risk factors involved in the intrauterine environment affects fetal development and thus increase the development risk of specific diseases in adult life as per the hypothesis of the fetal origins of adult disease (FOAD). The structural and molecular changes in the feto-maternal interface support and protect the semiallogeneic fetus from immune-mediated or inflammatory injury. On the other hand, the trophoblast cells of placenta facilitate the replication of HPV and the affliction of placenta and the vaginal infection can directly be associated with pregnancy outcomes. So, to optimize better child health care and reproductive outcomes, HPV screening might help during pregnancy. It is therefore important to understand how the HPV is affecting the early pregnancy and immune cells within the feto-maternal interface are educated for self-clearance to fulfill their biological functions or prevalence to affect the pregnancy outcomes and how the persistence of HR-HPV infection overtime increases the development of cervical cancer risk.

show abstract

Is HPV vaccination in pregnancy safe?

Cited by 26 publications

References 20 publications

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus

HPV infection and pre-term birth: a data-linkage study using Scottish Health Data

Human Papillomavirus Infections in Pregnant Women and Its Impact on Pregnancy Outcomes: Possible Mechanism of Self-Clearance

Contact Info

Product

Resources

About